Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARADIGM CORPARDM · Entity 155143 | Director | June 29, 2018 | July 03, 2018 |
| SUPERNUS PHARMACEUTICALS, INC.SUPN · Entity 4333 | Director | March 12, 2026 | March 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARADIGM CORP
Report date June 29, 2018 · Filed July 03, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.45 · Expires 2028-06-29 | Direct | 97,323 |
Reported balance
After 2018-06-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-29 · Grant · Acquired 97,323 · Balance 97,323 F1: The shares underlying the option shall vest and become exercisable in four equal quarterly installments over one year beginning on June 29, 2018, subject to such individual continuing to be a Participant (as defined in the 2015 Equity Incentive Plan) on the relevant vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the option shall vest and become exercisable in four equal quarterly installments over one year beginning on June 29, 2018, subject to such individual continuing to be a Participant (as defined in the 2015 Equity Incentive Plan) on the relevant vesting dates.
SUPERNUS PHARMACEUTICALS, INC.
Report date March 12, 2026 · Filed March 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 60,413 |
Reported balance
After 2026-03-12 transaction · row 1
1 source rowRow 1 · 2026-03-12 · Sale · Disposed 5,369 · Balance 60,413 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.45 to $50.82. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc., any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.45 to $50.82. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc., any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
scPharmaceuticals Inc.
Report date October 07, 2025 · Filed October 07, 2025
Section 16 reporting ended · disclosed 2025-10-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.85 · Expires 2035-06-03 | Direct | 0 |
Reported balance
After 2025-10-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-10-07 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, F2: (Continued from footnote 1) was cancelled and converted into the right to receive (i) an amount in cash, without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.11 · Expires 2034-06-11 | Direct | 0 |
Reported balance
After 2025-10-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-10-07 · Disposition to issuer · Disposed 19,750 · Balance 0 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, F2: (Continued from footnote 1) was cancelled and converted into the right to receive (i) an amount in cash, without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.53 · Expires 2032-06-14 | Direct | 0 |
Reported balance
After 2025-10-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-10-07 · Disposition to issuer · Disposed 16,300 · Balance 0 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, F2: (Continued from footnote 1) was cancelled and converted into the right to receive (i) an amount in cash, without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.37 · Expires 2029-06-18 | Direct | 0 |
Reported balance
After 2025-10-07 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-10-07 · Disposition to issuer · Disposed 6,124 · Balance 0 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, F2: (Continued from footnote 1) was cancelled and converted into the right to receive (i) an amount in cash, without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable,
F2: (Continued from footnote 1) was cancelled and converted into the right to receive (i) an amount in cash, without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 12, 2026 Filed Mar 16, 2026 16:07 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 5,369 | $50.61 | $271,725.09 |
DisclosureSEC source: 0001438462-26-000006 · wk-form4_1773691657.xml · nonDerivative · entry 1 Hudson Frederick M. · CIK 0001438462 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,413 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.45 to $50.82. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc., any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| February 24, 2026 Filed Feb 25, 2026 16:56 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Disposition to issuerRestricted Stock Unit · Derivative | 4,475 | $0.00 | $0.00 |
DisclosureSEC source: 0001438462-26-000004 · wk-form4_1772056609.xml · derivative · entry 2 Hudson Frederick M. · CIK 0001438462 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,475 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F2 · derivative.exercise_date: These restricted stock units will be settled in common stock upon vesting, which will occur on February 19, 2026. F2 · derivative.expiration_date: These restricted stock units will be settled in common stock upon vesting, which will occur on February 19, 2026. Read SEC document |
| February 24, 2026 Filed Feb 25, 2026 16:56 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantCommon Stock | 4,475 | $0.00 | $0.00 |
DisclosureSEC source: 0001438462-26-000004 · wk-form4_1772056609.xml · nonDerivative · entry 1 Hudson Frederick M. · CIK 0001438462 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,782 Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 16:39 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantDirector Stock Option (Right to Buy) · Derivative | 4,977 | $0.00 Strike: $50.20 | $0.00 |
DisclosureSEC source: 0001438462-26-000002 · wk-form4_1771623548.xml · derivative · entry 2 Hudson Frederick M. · CIK 0001438462 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,977 Underlying: Common Stock · 4,977 shares Expires 2036-02-18 F3 · derivative.exercise_date: Each option vests on February 18, 2027. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 16:39 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantRestricted Stock Unit · Derivative | 2,989 | $0.00 | $0.00 |
DisclosureSEC source: 0001438462-26-000002 · wk-form4_1771623548.xml · derivative · entry 1 Hudson Frederick M. · CIK 0001438462 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,989 Underlying: Common Stock · 2,989 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F2 · derivative.exercise_date: These restricted stock units will be settled in common stock upon vesting, which will occur on February 18, 2027. F2 · derivative.expiration_date: These restricted stock units will be settled in common stock upon vesting, which will occur on February 18, 2027. Read SEC document |
| January 09, 2026 Filed Jan 12, 2026 16:09 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionDirector Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $12.98 | $0.00 |
DisclosureSEC source: 0001628280-26-001817 · wk-form4_1768252183.xml · derivative · entry 2 Hudson Frederick M. · CIK 0001438462 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2026-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 09, 2026 Filed Jan 12, 2026 16:09 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 15,000 | $12.98 | $194,700.00 |
DisclosureSEC source: 0001628280-26-001817 · wk-form4_1768252183.xml · nonDerivative · entry 1 Hudson Frederick M. · CIK 0001438462 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,307 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 07, 2025 Filed Oct 7, 2025 16:30 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | Disposition to issuerStock Option (Right to Buy) · Derivative | 6,124 | $0.00 Strike: $3.37 | $0.00 |
DisclosureSEC source: 0001193125-25-233534 · ownership.xml · derivative · entry 4 Hudson Frederick M. · CIK 0001438462 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,124 shares Expires 2029-06-18 F1 · derivative.exercise_date: In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, F2 · derivative.exercise_date: (Continued from footnote 1) was cancelled and converted into the right to receive (i) an amount in cash, without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option. Read SEC document |
| October 07, 2025 Filed Oct 7, 2025 16:30 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | Disposition to issuerStock Option (Right to Buy) · Derivative | 16,300 | $0.00 Strike: $4.53 | $0.00 |
DisclosureSEC source: 0001193125-25-233534 · ownership.xml · derivative · entry 3 Hudson Frederick M. · CIK 0001438462 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,300 shares Expires 2032-06-14 F1 · derivative.exercise_date: In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, F2 · derivative.exercise_date: (Continued from footnote 1) was cancelled and converted into the right to receive (i) an amount in cash, without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option. Read SEC document |
| October 07, 2025 Filed Oct 7, 2025 16:30 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | Disposition to issuerStock Option (Right to Buy) · Derivative | 19,750 | $0.00 Strike: $4.11 | $0.00 |
DisclosureSEC source: 0001193125-25-233534 · ownership.xml · derivative · entry 2 Hudson Frederick M. · CIK 0001438462 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,750 shares Expires 2034-06-11 F1 · derivative.exercise_date: In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, F2 · derivative.exercise_date: (Continued from footnote 1) was cancelled and converted into the right to receive (i) an amount in cash, without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option. Read SEC document |
| October 07, 2025 Filed Oct 7, 2025 16:30 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | Disposition to issuerStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001193125-25-233534 · ownership.xml · derivative · entry 1 Hudson Frederick M. · CIK 0001438462 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2035-06-03 F1 · derivative.exercise_date: In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, F2 · derivative.exercise_date: (Continued from footnote 1) was cancelled and converted into the right to receive (i) an amount in cash, without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option. Read SEC document |
| August 14, 2025 Filed Aug 18, 2025 16:28 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 7,457 | $42.26 | $315,132.82 |
DisclosureSEC source: 0001628280-25-040662 · wk-form4_1755548919.xml · nonDerivative · entry 1 Hudson Frederick M. · CIK 0001438462 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,307 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.14 to $42.37. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 16:48 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0000950170-25-082434 · ownership.xml · derivative · entry 1 Hudson Frederick M. · CIK 0001438462 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2035-06-03 F1 · derivative.exercise_date: This stock option vests in full upon the earlier of (i) June 3, 2026, or (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| February 22, 2025 Filed Feb 24, 2025 17:50 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Disposition to issuerRestricted Stock Units · Derivative | 5,369 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-007479 · wk-form4_1740437446.xml · derivative · entry 2 Hudson Frederick M. · CIK 0001438462 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,369 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F2 · derivative.exercise_date: These restricted stock units were settled in common stock upon vesting, which occurred on February 22, 2025. F2 · derivative.expiration_date: These restricted stock units were settled in common stock upon vesting, which occurred on February 22, 2025. Read SEC document |
| February 22, 2025 Filed Feb 24, 2025 17:50 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantCommon Stock | 5,369 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-007479 · wk-form4_1740437446.xml · nonDerivative · entry 1 Hudson Frederick M. · CIK 0001438462 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,764 Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 16:51 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantRestricted Stock Unit · Derivative | 4,475 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-007191 · wk-form4_1740174702.xml · derivative · entry 3 Hudson Frederick M. · CIK 0001438462 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,475 Underlying: Common Stock · 4,475 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F3 · derivative.exercise_date: These restricted stock units will be settled in common stock upon vesting, which will occur on February 19, 2026. F3 · derivative.expiration_date: These restricted stock units will be settled in common stock upon vesting, which will occur on February 19, 2026. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 16:51 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantDirector Stock Option (Right to Buy) · Derivative | 7,296 | $0.00 Strike: $33.52 | $0.00 |
DisclosureSEC source: 0001628280-25-007191 · wk-form4_1740174702.xml · derivative · entry 2 Hudson Frederick M. · CIK 0001438462 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,296 Underlying: Common Stock · 7,296 shares Expires 2035-02-19 F1 · derivative.exercise_date: The option vests on February 19, 2026. Read SEC document |
| January 22, 2025 Filed Jan 23, 2025 16:33 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionDirector Stock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $9.13 | $0.00 |
DisclosureSEC source: 0001628280-25-002388 · wk-form4_1737668026.xml · derivative · entry 2 Hudson Frederick M. · CIK 0001438462 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2025-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 22, 2025 Filed Jan 23, 2025 16:33 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 20,000 | $9.13 | $182,600.00 |
DisclosureSEC source: 0001628280-25-002388 · wk-form4_1737668026.xml · nonDerivative · entry 1 Hudson Frederick M. · CIK 0001438462 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,395 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 08, 2024 Filed Nov 12, 2024 16:14 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 8,722 | $36.28 | $316,434.16 |
DisclosureSEC source: 0001628280-24-047152 · wk-form4_1731446048.xml · nonDerivative · entry 1 Hudson Frederick M. · CIK 0001438462 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,395 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.25 to $36.31. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 17:00 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | GrantStock Option (Right to Buy) · Derivative | 19,750 | $0.00 Strike: $4.11 | $0.00 |
DisclosureSEC source: 0000950170-24-073125 · ownership.xml · derivative · entry 1 Hudson Frederick M. · CIK 0001438462 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,750 Underlying: Common Stock · 19,750 shares Expires 2034-06-11 F1 · derivative.exercise_date: This stock option vests in full upon the earlier of (i) June 11, 2025, or (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 17:03 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Disposition to issuerRestricted Stock Unit · Derivative | 3,886 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-028278 · tm247055-18_4seq1.xml · derivative · entry 2 Hudson Frederick M. · CIK 0001438462 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,886 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F2 · derivative.exercise_date: These restricted stock units are settled in common stock upon vesting, which occurred on February 23, 2024. F2 · derivative.expiration_date: These restricted stock units are settled in common stock upon vesting, which occurred on February 23, 2024. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 17:03 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantCommon Stock | 3,886 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-028278 · tm247055-18_4seq1.xml · nonDerivative · entry 1 Hudson Frederick M. · CIK 0001438462 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,117 Read SEC document |
| February 22, 2024 Filed Feb 26, 2024 17:01 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantRestricted Stock Units · Derivative | 5,369 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-027574 · tm247055-11_4seq1.xml · derivative · entry 3 Hudson Frederick M. · CIK 0001438462 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,369 Underlying: Common Stock · 5,369 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F3 · derivative.exercise_date: These restricted stock units will be settled in common stock upon vesting, which will occur on February 22, 2025. F3 · derivative.expiration_date: These restricted stock units will be settled in common stock upon vesting, which will occur on February 22, 2025. Read SEC document |
| February 22, 2024 Filed Feb 26, 2024 17:01 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantDirector Stock Option (Right to Buy) · Derivative | 8,252 | $0.00 Strike: $27.94 | $0.00 |
DisclosureSEC source: 0001104659-24-027574 · tm247055-11_4seq1.xml · derivative · entry 2 Hudson Frederick M. · CIK 0001438462 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,252 Underlying: Common Stock · 8,252 shares Expires 2034-02-22 F1 · derivative.exercise_date: The option vests on February 22, 2025. Read SEC document |
| November 15, 2023 Filed Nov 17, 2023 17:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionDirector Stock Option (Right to Buy) · Derivative | 7,457 | $0.00 Strike: $9.24 | $0.00 |
DisclosureSEC source: 0001104659-23-119592 · tm2331055-1_4seq1.xml · derivative · entry 4 Hudson Frederick M. · CIK 0001438462 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,457 shares Expires 2024-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2023 Filed Nov 17, 2023 17:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 5,211 | $28.50 | $148,513.50 |
DisclosureSEC source: 0001104659-23-119592 · tm2331055-1_4seq1.xml · nonDerivative · entry 3 Hudson Frederick M. · CIK 0001438462 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,231 Read SEC document |
| November 15, 2023 Filed Nov 17, 2023 17:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 3,882 | $28.50 | $110,637.00 |
DisclosureSEC source: 0001104659-23-119592 · tm2331055-1_4seq1.xml · nonDerivative · entry 2 Hudson Frederick M. · CIK 0001438462 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,442 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.49 to $28.53, inclusive. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| November 15, 2023 Filed Nov 17, 2023 17:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 7,457 | $9.24 | $68,902.68 |
DisclosureSEC source: 0001104659-23-119592 · tm2331055-1_4seq1.xml · nonDerivative · entry 1 Hudson Frederick M. · CIK 0001438462 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,324 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 16:15 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | GrantStock Option (Right to Buy) · Derivative | 17,300 | $0.00 Strike: $11.71 | $0.00 |
DisclosureSEC source: 0000899243-23-014858 · doc4.xml · derivative · entry 1 Hudson Frederick M. · CIK 0001438462 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,300 Underlying: Common Stock · 17,300 shares Expires 2033-06-06 F1 · derivative.exercise_date: This stock option vests in full upon the earlier of (i) June 6, 2024, or (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 17:02 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantRestricted Stock Units · Derivative | 3,886 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-026082 · tm237737-16_4seq1.xml · derivative · entry 3 Hudson Frederick M. · CIK 0001438462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,886 Underlying: Common Stock · 3,886 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F3 · derivative.exercise_date: These restricted stock units will be settled in common stock upon vesting, which will occur on February 23, 2024. F3 · derivative.expiration_date: These restricted stock units will be settled in common stock upon vesting, which will occur on February 23, 2024. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 17:02 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantDirector Stock Option (Right to Buy) · Derivative | 6,293 | $0.00 Strike: $38.60 | $0.00 |
DisclosureSEC source: 0001104659-23-026082 · tm237737-16_4seq1.xml · derivative · entry 2 Hudson Frederick M. · CIK 0001438462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,293 Underlying: Common Stock · 6,293 shares Expires 2033-02-23 F1 · derivative.exercise_date: The option vests on February 23, 2024. Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 17:11 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Disposition to issuerRestricted Stock Units · Derivative | 3,882 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-025376 · tm237737-2_4seq1.xml · derivative · entry 2 Hudson Frederick M. · CIK 0001438462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,882 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F2 · derivative.exercise_date: These restricted stock units were settled in common stock upon vesting, which occurred on February 22, 2023. F2 · derivative.expiration_date: These restricted stock units were settled in common stock upon vesting, which occurred on February 22, 2023. Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 17:11 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantCommon Stock | 3,882 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-025376 · tm237737-2_4seq1.xml · nonDerivative · entry 1 Hudson Frederick M. · CIK 0001438462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,867 Read SEC document |
| January 10, 2023 Filed Jan 12, 2023 17:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionDirector Stock Option (Right to Buy) · Derivative | 8,722 | $0.00 Strike: $7.90 | $0.00 |
DisclosureSEC source: 0001104659-23-003461 · tm233200-3_4seq1.xml · derivative · entry 2 Hudson Frederick M. · CIK 0001438462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,722 shares Expires 2023-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 10, 2023 Filed Jan 12, 2023 17:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 8,722 | $7.90 | $68,903.80 |
DisclosureSEC source: 0001104659-23-003461 · tm233200-3_4seq1.xml · nonDerivative · entry 1 Hudson Frederick M. · CIK 0001438462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,985 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 14, 2022 Filed Jun 15, 2022 16:30 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | GrantStock Option (Right to Buy) · Derivative | 16,300 | $0.00 Strike: $4.53 | $0.00 |
DisclosureSEC source: 0000899243-22-022578 · doc4.xml · derivative · entry 1 Hudson Frederick M. · CIK 0001438462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,300 Underlying: Common Stock · 16,300 shares Expires 2032-06-14 F1 · derivative.exercise_date: This stock option vests in full upon the earlier of (i) June 14, 2023, or (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 21:24 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantRestricted Stock Units · Derivative | 3,882 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-026876 · tm227622-3_4seq1.xml · derivative · entry 3 Hudson Frederick M. · CIK 0001438462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,882 Underlying: Common Stock · 3,882 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F2 · derivative.exercise_date: These restricted stock units will be settled in common stock upon vesting, such vesting to occur on February 22, 2023. F2 · derivative.expiration_date: These restricted stock units will be settled in common stock upon vesting, such vesting to occur on February 22, 2023. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 21:24 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantDirector Stock Option (Right to Buy) · Derivative | 6,847 | $0.00 Strike: $32.20 | $0.00 |
DisclosureSEC source: 0001104659-22-026876 · tm227622-3_4seq1.xml · derivative · entry 2 Hudson Frederick M. · CIK 0001438462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,847 Underlying: Common Stock · 6,847 shares Expires 2032-02-22 Read SEC document |
| February 19, 2022 Filed Feb 23, 2022 16:16 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Disposition to issuerRestricted Stock Units · Derivative | 4,222 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-026100 · tm227492d2_4seq1.xml · derivative · entry 2 Hudson Frederick M. · CIK 0001438462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,222 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F2 · derivative.exercise_date: These restricted stock units were settled in common stock upon vesting, which occurred on February 19, 2022. F2 · derivative.expiration_date: These restricted stock units were settled in common stock upon vesting, which occurred on February 19, 2022. Read SEC document |
| February 19, 2022 Filed Feb 23, 2022 16:16 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantCommon Stock | 4,222 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-026100 · tm227492d2_4seq1.xml · nonDerivative · entry 1 Hudson Frederick M. · CIK 0001438462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,263 Read SEC document |
| June 08, 2021 Filed Jun 10, 2021 16:45 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | GrantStock Option (Right to Buy) · Derivative | 16,300 | $0.00 Strike: $5.70 | $0.00 |
DisclosureSEC source: 0000899243-21-022974 · doc4.xml · derivative · entry 1 Hudson Frederick M. · CIK 0001438462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,300 Underlying: Common Stock · 16,300 shares Expires 2031-06-08 F1 · derivative.exercise_date: This stock option vests in full upon the earlier of (i) June 8, 2022, and (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 18:47 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantRestricted Stock Units · Derivative | 4,222 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-026928 · tm217706-3_4seq1.xml · derivative · entry 3 Hudson Frederick M. · CIK 0001438462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,222 Underlying: Common Stock · 4,222 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F2 · derivative.exercise_date: These shares will be settled in common stock upon vesting, such vesting to occur on February 19, 2022. F2 · derivative.expiration_date: These shares will be settled in common stock upon vesting, such vesting to occur on February 19, 2022. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 18:47 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantDirector Stock Option (Right to Buy) · Derivative | 7,365 | $0.00 Strike: $29.61 | $0.00 |
DisclosureSEC source: 0001104659-21-026928 · tm217706-3_4seq1.xml · derivative · entry 2 Hudson Frederick M. · CIK 0001438462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,365 Underlying: Common Stock · 7,365 shares Expires 2031-02-19 Read SEC document |
| July 13, 2020 Filed Jul 15, 2020 16:39 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionDirector Stock Option (Right to Buy) · Derivative | 8,750 | $0.00 Strike: $2.56 | $0.00 |
DisclosureSEC source: 0001104659-20-083754 · a4.xml · derivative · entry 3 Hudson Frederick M. · CIK 0001438462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,750 shares Expires 2020-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted June 12, 2020. Read SEC document |
| July 13, 2020 Filed Jul 15, 2020 16:39 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 920 | $24.44 | $22,484.80 |
DisclosureSEC source: 0001104659-20-083754 · a4.xml · nonDerivative · entry 2 Hudson Frederick M. · CIK 0001438462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,041 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted June 12, 2020. F2 · balance_after: Includes 5,211 restricted stock units previously reported that will be settled in common stock upon vesting, such vesting to occur on February 21, 2021. Read SEC document |
| July 13, 2020 Filed Jul 15, 2020 16:39 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 8,750 | $2.56 | $22,400.00 |
DisclosureSEC source: 0001104659-20-083754 · a4.xml · nonDerivative · entry 1 Hudson Frederick M. · CIK 0001438462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,961 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted June 12, 2020. F2 · balance_after: Includes 5,211 restricted stock units previously reported that will be settled in common stock upon vesting, such vesting to occur on February 21, 2021. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 16:16 UTC | scPharmaceuticals Inc. SCPH · Entity 74456 | GrantStock Option (Right to Buy) · Derivative | 6,124 | $0.00 Strike: $7.96 | $0.00 |
DisclosureSEC source: 0000899243-20-016167 · doc4.xml · derivative · entry 1 Hudson Frederick M. · CIK 0001438462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,124 Underlying: Common Stock · 6,124 shares Expires 2030-06-09 F1 · derivative.exercise_date: This stock option vests in full upon the earlier of (i) June 9, 2021, and (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 17:24 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantDirector Stock Option (Right to Buy) · Derivative | 9,305 | $0.00 Strike: $23.99 | $0.00 |
DisclosureSEC source: 0001104659-20-024852 · a4.xml · derivative · entry 2 Hudson Frederick M. · CIK 0001438462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,305 Underlying: Common Stock · 9,305 shares Expires 2030-02-21 Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 17:24 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantCommon Stock | 5,211 | $23.99 | $125,011.89 |
DisclosureSEC source: 0001104659-20-024852 · a4.xml · nonDerivative · entry 1 Hudson Frederick M. · CIK 0001438462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,211 F1 · shares: Represents restricted stock unit component of the annual equity compensation to directors. These shares will be settled in common stock upon vesting, such vesting to occur on February 21, 2021. Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.